Biotechnology company Biocon announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Consolidated Total Revenue for Q4FY25 was Rs 4,454 crore, a growth of 12% over last year and 15% sequentially. On a like-for-like basis, Total Revenue grew 15% YoY after adjusting for revenues from Branded Formulations India (BFI). Group Core EBITDA for the quarter stood at Rs 1,363 crore, Up 16% from last year, with a healthy Core Operating margin of 31%. Quarterly R&D; Investment stood at Rs 231 crore corresponding to 7% of revenues ex -Syngene. EBITDA for the quarter stood at Rs 1,115 crore, Up 16% with a margin of 25%. Profit Before Tax at Rs 487 crore was Up 53%. Net Profit after exceptional item for the quarter stood at Rs 344 crore, Up 153%. On a like for like basis Net profit was up 162%. FY25 Financial Highlights: Consolidated Total Revenue for FY25 came in at Rs 16,470 crore, a growth of 5% YoY. Total Revenue grew 8% YoY on a like-for-like basis, after adjusting for revenues and divestment gain from BFI and stake dilution gain in Bicara. Group Core EBITDA was up 2% to Rs 4,264 crore, representing a core operating margin of 28%. R&D; investments for the full year stood at Rs 859 crore, and representing 7% of revenues ex-Syngene. EBITDA for the year was up 5% at Rs 4,374 crore vs Rs 4,164 crore in the same period last year, with an EBITDA margin of 27%. Profit Before Tax stood at Rs 1,887 crore, up 24% YoY. Net Profit for FY25 is Rs 1,013 crore vs last fiscal's Rs 1,022 crore, which included Bicara gain & income from part divestment of BFI business by Biocon Biologics. On a like-for-like basis, Net Profit grew 30% after adjusting for the revenues from BFI, BFI divestment gain and dilution/fair valuation gain in Bicara. Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said: “The Biocon Group ended the year with a strong performance across its businesses. The launch of Liraglutide in the UK market heralded our entry into the GLP-1 therapy segment. Our Biosimilars continue to build impressive shares in global markets with four biosimilars recording sales of USD 200 million each in FY25. We also launched our fifth biosimilar product Yesintek™ (bUstekinumab) in the U.S. market. This quarter marked the expansion of Syngene’s biologics manufacturing footprint through an acquisition of a state-of-the-art manufacturing facility in the U.S. “FY25 has been a year of consolidation and transition. We are now on a path of accelerating growth with a commitment to innovation, digital augmentation and operational excellence.” Siddharth Mittal, CEO & Managing Director, Biocon, said: “The Generics business delivered a healthy 46% YoY and a robust 53% sequential growth in Q4, concluding FY25 with an overall 8% growth over the previous year. The performance was primarily driven by contributions from new product launches, notably Lenalidomide and Dasatinib in the U.S., supported by modest growth in our API business. “Looking ahead, we remain focused on the strategic expansion of our differentiated GLP-1 portfolio into new markets, which will position us well for growth. In FY26, we also expect to see a recovery in the API business, aided by our cost improvement initiatives, enhancement of operational efficiencies, and new capacities coming on-stream.” Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: “Biocon Biologics continued its growth momentum in Q4FY25, delivering a robust 9% YoY revenue increase driven by significant market share gains in the U.S. and key tender wins in Emerging Markets. Regulatory approvals of our manufacturing facilities from USFDA and EMA have enabled the launch of Yesintek™, our bUstekinumab, in the U.S. and Europe. The successful settlement of our patent litigation has allowed us to secure a market entry date for Yesafili™, our bAflibercept, in the U.S. "On a full-year basis, the Company has recorded a strong 15% growth in FY25 and we have successfully consolidated our business worldwide. Having built a strong foundation, we are well positioned to launch 5 new products in the next 12-18 months and expand patient access.” Peter Bains, CEO & Managing Director, Syngene International, said: “Syngene reported Q4FY25 revenue growth of 11% YoY, and 8% sequentially, crossing the Rs. 1,000 crore in a quarter threshold for the first time. At the EBITDA level, growth was 9% YoY reflecting good underlying fundamentals. The full year results, led by reported revenue growth of 4%, are in line with our earlier guidance, reflecting a resilient performance in a challenging year marked by a sectoral downturn in U.S. biotech funding. We continued to make strategic investments to enhance our capabilities and capacities across business while maintaining a strong balance sheet and an improved net cash position. “Looking at the year ahead, while the wider global market dynamics remain uncertain, the positive momentum that drove Syngene's return to growth in the latter half of FY25 is expected to continue into FY26, with projected revenue growth in the mid-single digits.” Result PDF